Allergy advocacy group Food Allergy Research and Education says that the U.S. is facing a growing national shortage of EpiPens and other allergic reaction treatments called epinephrine auto-injectors. Individuals with food allergies have found it difficult to fill their prescriptions in as many as 14 states as of late April, the group said. The American Society of Health-System Pharmacists, a professional organization for pharmacists, also said that there was a shortage of Mylan's EpiPen with the EpiPen, EpiPen Jr. for children and the authorized generic version "on intermittent back order with regular releases," earlier this month. A rival product manufactured by Kaleo was still available, the group said. The Food and Drug Administration did not immediately return MarketWatch's request for comment, but a spokesperson said in late April that it was not aware at that time of any shortage. A FDA spokesperson then called it a "spot shortage" in late April, according to the publication Allergic Living. The advocacy group FARE said it wrote to FDA Commissioner Scott Gottlieb on May 1 about its concerns, and said on Monday that it was calling on the FDA to declare the issue a national shortage. EpiPen shortages have been seen in Canada and the United Kingdom. FARE also questioned whether there was a connection between the supply issues and problems at a Pfizer unit that manufactures the EpiPen, and asked the FDA to push for other allergic reaction treatments from Teva and Adamis Pharmaceuticals Corp. which got its Symjepi product approved last July, though the product has not been brought to market.